Target
AstraZeneca
5 abstracts
Abstract
The pathway alteration load as a pan-cancer determinant of outcome of targeted therapies: Results from the Drug Rediscovery Protocol (DRUP).Org: Department of Molecular Oncology & Immunology, Netherlands Cancer Institute (Netherlands), Hartwig Medical Foundation, Erasmus Medical Cancer Institute, Department of Biometrics,
Abstract
The evolving value assessment of cancer therapies: Principles from the cancer community.Org: The Boston Consulting Group, Lung cancer Europe, The Susan G. Komen Breast Cancer Foundation, Inc., Cancer Technology Applications, International Breast Cancer Centre (IBCC),
Abstract
Prevalence of risk factors for liver fibrosis and associations of serum biomarkers with liver fibrosis in a Houston community clinic.Org: University of Texas MD Anderson Cancer Center, The University of Texas Health Science Center at Houston (UTHealth), School of Public Health, Fudan University, Baylor Scott & White Health, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
Making decisions about clinical trial enrollment: What’s important to the patient?Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Houston, TX,
Abstract
Improving guideline-concordant biomarker testing through implementation of a precision cancer medicine steward.Org: Association of Community Cancer Centers (ACCC), Rockville, MD, Xaf Solutions, Memorial Cancer Institute, Sanford USD Medical Center, TriHealth Cancer Institute,